Day #1: october 13, 2010
DVD 1: Plenary Session I
DVD 3: Chronic Lymphocytic Leukemia,
Molecular Abnormalities and Gene Expression
Changes in AML. Are we Ready for a Prognostic
Debate: Fludarabine vs. Chlorambucil. Is the Battle
Molecular Prioritization? What is the impact on
Personalized AML Therapy?
Torsten Haferlach, MD
Chlorambucil – Still Not Bad
CLL: How Much Progress? What is the Future?
Michael J. Keating, MB, BS
Fludarabine the Winner
Close to the Cure in CML
IMIDs Combinations in CLL
How Can We Exploit the CLL Microenvironment?
Jan A. Burger, MD, PhD
DVD 2: Chronic Lymphocytic Leukemia,
FCR Now Frontline Therapy
DVD 4: Acute Lymphoblastic Leukemia
Treatment of Adolescents and Young Adults –
Do the Biologic Factors add any Significance over
Pediatric versus Adult Regimens?
the Clinical and Classical Prognostic Factors?
Monoclonal Antibodies in ALL Therapy – Any
Role of Old and New Monoclonal Antibodies, Alone
and in Combinations
Targeted Therapies in Ph-positive ALL: Which is the
Novel Inhibitors of B-Cell Signaling
Best TKI? What is the Role of Chemotherapy?
Transplant in CLL--When, How, and What to Expect
Minimal Residual Disease: What Does it Mean? Is
it now a Therapeutic Target?
What do the Genetics Tell us? Can we Translate the
Findings into Therapies?
Novel Drugs and Strategies in ALL: Breakthroughs
on the Horizon?
Treatment in CLL - the Age Old Question
Allogeneic SCT for ALL in CR1: Grounds for
DVD 5: Myeloproliferative Disorders
DVD 7: Myelodysplastic Syndromes
Pathophysiology of MPDs and Role of JAK2
SNPs and other Molecular Changes in MDS – Ready
JAK2 Inhibitors – Are they the Solution?
Novel Pathophysiologic Pathways in MDS
Role of IMIDs in Myelofibrosis
IMIDs in MDS -- What Have We Learned So Far?
Interferon Alfa in PV and ET
Prognostic Factors and Risk Models in MDS
Prognostic Factors and Models in PV, ET, and MF
Debate: Role of Allogeneic SCT in MDS
Critical to Cure MDS
Theo de Witte, MD, PhD
DVD 6: Myelodysplastic Syndromes
Part I, Plenary Session II
Minimal Benefit in MDS
Progress with Epigenetic Therapy in MDS – Are We
Novel Agents and Strategies in MDS
Plenary Session II
Growth Factors (EPO, GCSF, TPO) in the Modern Era
Eva S. Hel ström-Lindberg, MD, PhD
Cure of Myeloma, A Personal Odyssey
Any Progress in MPDs?
Ayalew Tefferi, MD
DVD 8: Acute Myeloid Leukemia Part I
State of the Art Therapy of Younger AML – Lesson
Debate: Iron Chelation Therapy in MDS – Is it
from Large Randomized Clinical Trials
Absolutely Necessary to Improve Outcome
Debate: Treatment of Older AML
Intensive Chemotherapy is the Best Approach
No Data to Prove its Benefit
Low Intensity Therapy is the Way of the Future
DVD 8: Acute Myeloid Leukemia Part I
DVD 10: Multiple Myeloma (…cont)
State of the Art Therapy of APL – The Lo Coco
Adverse Cytogenetic and Biologic Factors in
Role of Allogeneic SCT in CR1
IMIDs, Proteosome Inhibitors, Combos. What is
FLT3 Mutations and FLT3 Inhibitors – Last Nail in
Coffin or Resuscitation
Waldenstrom’s Macroglobulinemia – Where does
New Treatments and Strategies in AML
DVD 11: Lymphoma
DVD 9: Acute Myeloid Leukemia Part II
Any Progress Since R-CHOP?
Marrow Microenvironment and Targeted Therapies
Is Bendamustine + Rituxan the Best Treatment for
Micro RNA and Molecular Profiling in AML – Is it
What is Optimal Therapy in Early Large Cell
WBC Transfusions, Irradiated, Unirradiated?
Indolent Lymphomas – Observe, BR, RCHOP,
DVD 10: Multiple Myeloma
Hodgkin’s Disease – Cured but not Conquered
Pathophysiology of Myeloma – Lessons into the
SCT Improves Outcome in Myeloma
Bart Barlogie, MD Novel Agents and Combinations in Myeloma
Antonio Palumbo, MD
DVD 12: Chronic Myeloid Leukemia
DVD 13: Special Topics
Debate: What is the Ideal Frontline CML Therapy?
State of the Art New Antifungals
Dimitrios Kontoyiannis, MD
Allogeneic SCT in Leukemias – Overview
2nd Generation TKIs
Multipotent Mesenchymal Stromal Cells (MSC) –
Evolving Role in Cancer and Leukemia Therapy
Salvage Strategies Post Imatinib Failure – What to
Interesting Statistics in Leukemia
Debate: Optimal Monitoring in CML?
Intensive Monitoring is Essential
Too Much for Too Little
Debate: Role of Allogeneic SCT
As Salvage Post Imatinib Failure
As Salvage Post 2 TKI Failures
Do We Have Better Prognostic Tools in CML?
Can We Improve on Frontline CML Therapy?
LITTLE BROWNIE BAKERS/GIRL SCOUTS 2012-2013 SEASON – GS COOKIE (8) NLI’s Samoas ® Savannah SmilesTM Do-si-dos ® Thin Mints ® Nutrition Facts Nutrition Facts Nutrition Facts Nutrition Facts Amount Per Serving Amount Per Serving Amount Per Serving Amount Per Serving Calories 150 Calories from Fat 70 Calories 140 Calories from Fat 45 Calories 160
An Elephant’s Knowledge: Chronic Post Surgical Pain It was a busy Monday morning in theatres and I was already feeling anxious. My consultant was running late and Mrs Johnson, who was listed for a mastectomy was in tears. She said that her sister had had a mastectomy 8 years ago and that she had been in pain ever since; she was desperately worried the same thing would happen t